Eledon Pharmaceuticals, Inc.

NASDAQ:ELDN

Biotechnology

Healthcare
$2.03 +2.84%

+$0.11 today

Market cap
$171.45M
Beta
0.97
P/E (TTM)
-5.5
EPS (TTM)
-$0.70
52W Low $1.35High $4.60

Volume 1.12M

Average 1.37M

ELDN Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Eledon Pharmaceuticals, Inc.NASDAQ: ELDN

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow grows, but more slowly than its trailing trend

Q1 FY2026 investing cash flow of $5.96M rose 53.0% year over year, behind the +116.9% change in trailing-twelve-month investing cash flow.

Context

  • Investing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +53.0% toward the trailing-twelve-month pace of +116.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.96M+129.1% QoQ
Last fiscal yearDec 2025
$10.79M+115.3% YoY
LTMMar 2026
$12.86M+116.9% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+53.0%——
1 year+115.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
10.79M USD
Year-over-year change
+115.3%

Investing Cash Flow vs competitors

How ELDN compares with its peers on the latest reported figures

  • ELDN's LTM Mar 2026 investing cash flow of $12.86M is the 9th largest of the 11 companies compared; the peer median is $76.77M.
  • Its year-over-year change of +116.9% is the 5th highest of 11, against a peer median of +57.9%.
ELDN Competitors Peer median
Investing Cash Flow for ELDN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$139.01M +382.8%—2422.7%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$132.92M +56.5%——
ABEOAbeona Therapeutics Inc.LTM Mar 2026$105.78M +488.7%—727.5%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$92.35M +117.8%—253.0%
EDITEditas Medicine, Inc.LTM Mar 2026$82.35M -63.1%+6.7%212.8%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$71.19M +59.3%+23.9%32.7%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$59.8M +0.1%-3.4%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$35.25M -20472.8%—15.5%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$12.86M +116.9%——
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$9.03M +188.3%——
HUMAHumacyte, Inc.LTM Mar 2026$831K -41.0%—41.2%
Peer median (excluding ELDN) $76.77M+57.9%+6.7%212.8%

Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(34.51M)(87.97M)(116.54M)(36.18M)(45.62M)
Depreciation & Amortization195K373K374K359K313K
Deferred Income Tax(2.35M)00431K5K
Stock-Based Compensation7.9M8.15M6.55M13.12M10.45M
Change in Working Capital(152K)2.37M(4.92M)8.71M7.65M
Accounts Receivables00000
Inventory00000
Accounts Payables2.14M2.08M(2.6M)7.75M6.72M
Other Working Capital(2.3M)287K(2.32M)959K928K
Other Non-Cash Items048.65M75.01M(33.71M)(35.15M)
Operating Cash Flow(28.91M)(28.42M)(39.53M)(47.27M)(62.34M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00(78.29M)(156.13M)(161.13M)
Sales of Investments0033M85.82M171.93M
Other Investing Activities00000
Investing Cash Flow00(45.29M)(70.31M)10.79M
Debt Repayment00000
Common Stock Issued(449K)033.02M133.31M53.58M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities000215K0
Financing Cash Flow(449K)033.02M133.52M53.81M
Effect of Forex Changes00000
Net Change in Cash(29.36M)(28.42M)(51.8M)15.94M2.26M
Free Cash Flow(28.91M)(28.42M)(39.53M)(47.27M)(62.34M)

Eledon Pharmaceuticals, Inc.

NASDAQ:ELDN

Intrinsic Alpha fair value

Locked

Current Price

$2.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.